FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3627-3635

  Nakanishi, Ryota ^a   Kitao, Hiroyuki ^a   Fujinaka, Yoshihiko ^a   Yamashita, Nami ^a   Iimori, Makoto ^a   Tokunaga, Eriko ^a   Yamashita, Natsumi ^a   Morita, Masaru ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FANCJ PROTEIN; FANCONI ANEMIA PROTEIN; FLUOROURACIL; PROTEIN MLH1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; FEMALE; FLUOROURACIL; HCT116 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NUCLEAR PROTEINS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84868198877     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2349-8     Document Type: Article

References (40)

1. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939-44.
2. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295-300. (Pubitemid 28041612)
3. Wilkinson NW, Yothers G, Lopa S, et al. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17:959-66.
4. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27:1814-21.
5. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14:1413-7. (Pubitemid 351413923)
6. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10:5880-8. (Pubitemid 39180969)
7. Nobili S, Napoli C, Landini I, et al. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int J Cancer. 2011;128:1935-45.
8. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57. (Pubitemid 36859476)
9. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45:365-73.
10. Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7:1343-9. (Pubitemid 32708690)
11. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-70. (Pubitemid 26358996)
12. Tokunaga E, Oki E, Oda S, et al. Frequency of microsatellite instability in breast cancer determined by high-resolution fluorescent microsatellite analysis. Oncology. 2000;59:44-9. (Pubitemid 30435835)
13. Zavodna K, Bujalkova M, Krivulcik T, et al. Novel and recurrent germline alterations in the MLH1 and MSH2 genes identified in hereditary nonpolyposis colorectal cancer patients in Slovakia. Neoplasma. 2006;53:269-76. (Pubitemid 44105931)
14. Barrow E, Jagger E, Brierley J, et al. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome. Histopathology. 2010;56:331-44.
15. Park JW, Chang HJ, Park S, et al. Absence of hMLH1 or hMSH2 expression as a stage-dependent prognostic factor in sporadic colorectal cancers. Ann Surg Oncol. 2010;17:2839-46.
16. Peng M, Litman R, Xie J, et al. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. EMBO J. 2007;26:3238-49. (Pubitemid 47057494)
17. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37:931-3. (Pubitemid 43086147)
18. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23-34. (Pubitemid 37328884)
19. Cantor SB, Xie J. Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair. Environ Mol Mutagen. 2010;51:500-7.
20. Xie J, Guillemette S, Peng M, et al. An MLH1 mutation links BACH1/FANCJ to colon cancer, signaling, and insight toward directed therapy. Cancer Prev Res (Phila). 2010;3:1409-16.
21. Liu A, Yoshioka K, Salerno V, Hsieh P. The mismatch repairmediated cell cycle checkpoint response to fluorodeoxyuridine. J Cell Biochem. 2008;105:245-54.
22. Fischer F, Baerenfaller K, Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology. 2007;133:1858-68. (Pubitemid 350180806)
23. Jass JR, Sobin LH. Histological typing of intestinal tumours. WHO International Histological Classification of Tumours No. 15. 2nd ed. Berlin: Springer; 1989.
24. Sobin LH Wittekind Ch, eds. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002.
25. Eelen G, Vanden Bempt I, Verlinden L, et al. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene. 2008;27:4233-41. (Pubitemid 351969904)
26. Cantor SB, Bell DW, Ganesan S, et al. BACH1, a novel helicaselike protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001;105:149-60. (Pubitemid 32323924)
27. Yu X, Chini CC, He M, et al. The BRCT domain is a phosphoprotein binding domain. Science. 2003;302:639-42.
28. Takeuchi H, Baba H, Inutsuka S, et al. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer Res. 1994;14:169-71. (Pubitemid 24132107)
29. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376-80. (Pubitemid 41429560)
30. Oda S, Oki E, Maehara Y, Sugimachi K. Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res. 1997;25:3415-20. (Pubitemid 27359214)
31. Oki E, Oda S, Maehara Y, Sugimachi K. Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair. Oncogene. 1999;18:2143-7. (Pubitemid 29178583)
32. Oki E, Kakeji Y, Zhao Y, et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol. 2009;16:2510-5.
33. Oda S, Maehara Y, Ikeda Y, et al. Two modes of microsatellite instability in human cancer: Differential connection of defective DNA mismatch repair to dinucleotide repeat instability. Nucleic Acids Res. 2005;33:1628-36. (Pubitemid 41418390)
34. Tajiri T, Suita S, Shono K, et al. A microsatellite instability analysis in neuroblastoma based on a high resolution fluorescent microsatellite analysis. Cancer Lett. 1998;124:59-63. (Pubitemid 28073809)
35. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994;54:4308-12.
36. Russell WC. Update on adenovirus and its vectors. J Gen Virol. 2000;81:2573-604.
37. Rudland PS, Platt-Higgins AM, Davies LM, et al. Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol. 2010;176:2935-47.
38. Ozawa H, Iwatsuki M, Mimori K, et al. FANCD2 mRNA overexpression is a bona fide indicator of lymph node metastasis in human colorectal cancer. Ann Surg Oncol. 2010;17:2341-8.
39. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995;1: 305-11.
40. Xie J, Litman R, Wang S, et al. Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poletadependent bypass. Oncogene. 2010;29:2499-508.